| Stock Name | 九源基因 |
|---|---|
| Stock Code | 02566 |
| Company Full Name | 九源基因 |
| Industry | 醫療保健 |
| Principal Activities | 公司是一家總部設于浙江省的中國生物制藥公司，擁有逾30年生物藥品及醫療器械研發、生產及商業化經驗。 |
| Listing Date | 2024-11-28 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國浙江省杭州市錢塘區白楊街道8號大街23號 |
| Business Address (Hong Kong) | To be extracted |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | https://www.china-gene.com/ |
| Share Registrar | 卓佳证券登记有限公司 (Tricor Investor Services Limited) |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No data |
| Offering Mechanism | To be extracted |
|---|---|
| Offer Price | HK$ 12.42 / shares |
| Offer Price Range | To be extracted |
| Lot Size | To be extracted |
| Entry Threshold | To be extracted |
| Par Value | To be extracted |
| Offer Period | To be extracted |
| Global Offering Shares | To be extracted |
| HK Public Offer Shares (Initial) | To be extracted |
| Public Offer Lots (Initial) | To be extracted |
| International Placing Shares (Initial) | To be extracted |
| Offer Ratio | To be extracted |
| Total Shares Post-IPO | To be extracted |
| Greenshoe (Over-allotment Option) | To be confirmed |
| Stabilizing Manager (Greenshoe) | — |
| Cornerstone Share | 49.7% |
| Clawback Tiers | To be extracted |
| Reallocation Option | To be confirmed |
| Total Global Offering Size | HK$ 281,926,548 |
Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 1 lots | 200 | HK$ 2,484 |
| 2 lots | 400 | HK$ 4,968 |
| 3 lots | 600 | HK$ 7,452 |
| 4 lots | 800 | HK$ 9,936 |
| 5 lots | 1,000 | HK$ 12,420 |
| 6 lots | 1,200 | HK$ 14,904 |
| 7 lots | 1,400 | HK$ 17,388 |
| 8 lots | 1,600 | HK$ 19,872 |
| 9 lots | 1,800 | HK$ 22,356 |
| 10 lots | 2,000 | HK$ 24,840 |
| 15 lots | 3,000 | HK$ 37,260 |
| 20 lots | 4,000 | HK$ 49,680 |
| 25 lots | 5,000 | HK$ 62,100 |
| 30 lots | 6,000 | HK$ 74,520 |
| 35 lots | 7,000 | HK$ 86,940 |
| 40 lots | 8,000 | HK$ 99,360 |
| 45 lots | 9,000 | HK$ 111,780 |
| 50 lots | 10,000 | HK$ 124,200 |
| 100 lots | 20,000 | HK$ 248,400 |
| 150 lots | 30,000 | HK$ 372,600 |
| 200 lots | 40,000 | HK$ 496,800 |
| 250 lots | 50,000 | HK$ 621,000 |
| 300 lots | 60,000 | HK$ 745,200 |
| 350 lots | 70,000 | HK$ 869,400 |
| 400 lots | 80,000 | HK$ 993,600 |
| 450 lots | 90,000 | HK$ 1,117,800 |
| 500 lots | 100,000 | HK$ 1,242,000 |
| 750 lots | 150,000 | HK$ 1,863,000 |
| 1,000 lots | 200,000 | HK$ 2,484,000 |
| 1,250 lots | 250,000 | HK$ 3,105,000 |
| 1,500 lots | 300,000 | HK$ 3,726,000 |
| 1,750 lots | 350,000 | HK$ 4,347,000 |
| 2,000 lots | 400,000 | HK$ 4,968,000 |
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 2,250 lots | 450,000 | HK$ 5,589,000 |
| 2,500 lots | 500,000 | HK$ 6,210,000 |
| 3,000 lots | 600,000 | HK$ 7,452,000 |
| 3,500 lots | 700,000 | HK$ 8,694,000 |
| 4,000 lots | 800,000 | HK$ 9,936,000 |
| 4,500 lots | 900,000 | HK$ 11,178,000 |
| 5,000 lots | 1,000,000 | HK$ 12,420,000 |
| 7,500 lots | 1,500,000 | HK$ 18,630,000 |
| 10,000 lots | 2,000,000 | HK$ 24,840,000 |
| 11,350 lots | 2,270,000 | HK$ 28,193,400 |
| Market Cap (at Offer Price) | To be extracted |
|---|---|
| Pre-IPO Valuation (Last Round) | To be extracted |
| P/E Ratio | To be extracted |
| Profit/Loss Status | To be extracted |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
| First Day Close | HK$ 7.65 |
|---|---|
| First Day Open | HK$ 7.5 |
| First Day Change | -38.41% |
| First Day Volume | 28954400.0 |
| First Day Turnover | 246224000.0 |
| Use of Proceeds | 1、約40.0%（或187.3百萬港元）將分配至戰略性重點治療領域的選定在研產品的持續研發； 2、約30.0%（或140.4百萬港元）將用于現有及接近商業化產品的營銷及商業化； 3、約10.0%（或46.8百萬港元）將用于尋求戰略合作，以豐富在目標治療領域的產品組合； 4、約10.0%（或46.8百萬港元）將用于制造系統，以建設新生產線，并升級及進一步自動化現有生產設施，從而為產品的潛在需求增長及新產品的推出做好準備； 5、約10.0%（或46.8百萬港元）將用于為營運資金及其他一般企業用途提供資金。 |
|---|
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | Alibaba Health (Hong Kong) Technology Company Limited | 18,480,960 HKD | — | 3.28% | — | 6 months | 2025-05-28 |
| 2 | Delta Capital Hong Kong Limited | 9,598,176 HKD | — | 1.70% | — | 6 months | 2025-05-28 |
| 3 | Jointown International Group Company Limited | 18,667,260 HKD | — | 3.31% | — | 6 months | 2025-05-28 |
| 4 | 复星实业(香港)有限公司 | 31,112,100 HKD | — | 5.52% | — | 6 months | 2025-05-28 |
| 5 | 和达金源(香港)有限公司 | 154,012,968 HKD | — | 27.31% | — | 6 months | 2025-05-28 |
| 6 | 吴启元 | 17,005,464 HKD | — | 3.02% | — | 6 months | 2025-05-28 |
| 7 | 香港健友实业有限公司 | 31,112,100 HKD | — | 5.52% | — | 6 months | 2025-05-28 |
| Chairman | 傅航 |
|---|---|
| Company Secretary | 黃秀,何詠雅 |
| Major Shareholders & Holdings | 杭州中華東制藥有限公司(17.16%),杭州華升醫藥集團有限公司(13.24%),Corporacion Quimico-farmaceutica Esteve,Sociedad Anonima(12.22%),浙江網新科技創投有限公司(9.99%),Highland Pharma Limited(8.15%) |
|---|
Market Sentiment
九源基因 IPO attracted overwhelming investor interest, evidenced by an oversubscription ratio of 675.83, one of the highest in recent listings. The data indicates zero accepted applications among 30,759 valid submissions, reflecting an effective zero allocation rate and extreme share scarcity. This fervent demand suggests strong market confidence despite the HK$12.42 offer price. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)
Tier Analysis
Allocation patterns show a distinct anomaly: both 甲尾 (last A-tier) at 400,000 shares and 乙头 (first B-tier) at 450,000 shares received only 1 expected lot, neutralizing any tier advantage. This means larger applications with higher broker fees gained no extra benefit, highlighting cost inefficiency especially for those just entering the B-tier. The narrow gap between tiers amplifies this effect. (This is AI-generated commentary based on historical data. Broker fee structures vary and actual costs may differ. Not financial advice.)
Demographics
Provided demographic data is incomplete, with total holders, mainland China, and Hong Kong participation rates all recorded as zero, likely due to reporting gaps. Typically, high-demand IPOs see significant mainland participation, but no conclusions can be drawn without verified data. Investors should consult official HKEX filings for accurate distribution details. (This is AI-generated commentary based on historical data. Data may contain errors or omissions — verify against official HKEX filings. Not financial advice.)
